The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2018

AUTHORS

Karima Relizani , Aurelie Goyenvalle

ABSTRACT

Antisense oligonucleotides (AONs) hold great promise for therapeutic splice-switching correction in many genetic diseases and in particular for Duchenne muscular dystrophy (DMD), where AONs can be used to reframe the dystrophin transcript and give rise to a partially deleted but yet functional dystrophin protein. Many different chemistries of AONs can be used for splice switching modulation, and some of them have been evaluated in clinical trials for DMD. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake, and sufficient therapeutic efficacy is difficult to achieve. Therefore, there is still a critical need to develop efficient AONs able to restore the expression of dystrophin in all relevant tissues and international efforts are currently on going to develop new compounds or alternative chemistries with higher therapeutic potential. Here, we describe the methods to evaluate the potency of antisense oligonucleotides, and in particular of tricyclo-DNA (tcDNA)-AONs, a novel class of AONs which displays unique pharmacological properties and unprecedented uptake in many tissues after systemic administration. We focus on the most widely used mouse model for DMD, the mdx mouse and detail methods to analyze the skipping of the mouse exon 23 both in vitro in H2K mdx cells and in vivo in the mdx mouse model. More... »

PAGES

171-183

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4939-7374-3_12

DOI

http://dx.doi.org/10.1007/978-1-4939-7374-3_12

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092345489

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29067663


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1004", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Biotechnology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/10", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Technology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Models, Animal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dystrophin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Exons", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Inbred mdx", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Muscle, Skeletal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Muscular Dystrophy, Duchenne", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligonucleotides, Antisense", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Versailles Saint-Quentin-en-Yvelines University", 
          "id": "https://www.grid.ac/institutes/grid.12832.3a", 
          "name": [
            "Universit\u00e9 de Versailles St-Quentin en Yvelines", 
            "Universit\u00e9 de Versailles Saint-Quentin en Yvelines"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Relizani", 
        "givenName": "Karima", 
        "id": "sg:person.01026571624.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026571624.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Universit\u00e9 de Versailles St-Quentin en Yvelines"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goyenvalle", 
        "givenName": "Aurelie", 
        "id": "sg:person.01200571036.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200571036.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1073/pnas.81.4.1189", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001793181"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.coph.2015.07.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002005310"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/nar/gkp841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005271115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3233/jnd-160146", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013977294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.3765", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014266352", 
          "https://doi.org/10.1038/nm.3765"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/dbio.1994.1103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015861224"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/nar/29.9.e45", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030834024"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018", 
    "datePublishedReg": "2018-01-01", 
    "description": "Antisense oligonucleotides (AONs) hold great promise for therapeutic splice-switching correction in many genetic diseases and in particular for Duchenne muscular dystrophy (DMD), where AONs can be used to reframe the dystrophin transcript and give rise to a partially deleted but yet functional dystrophin protein. Many different chemistries of AONs can be used for splice switching modulation, and some of them have been evaluated in clinical trials for DMD. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake, and sufficient therapeutic efficacy is difficult to achieve. Therefore, there is still a critical need to develop efficient AONs able to restore the expression of dystrophin in all relevant tissues and international efforts are currently on going to develop new compounds or alternative chemistries with higher therapeutic potential. Here, we describe the methods to evaluate the potency of antisense oligonucleotides, and in particular of tricyclo-DNA (tcDNA)-AONs, a novel class of AONs which displays unique pharmacological properties and unprecedented uptake in many tissues after systemic administration. We focus on the most widely used mouse model for DMD, the mdx mouse and detail methods to analyze the skipping of the mouse exon 23 both in vitro in H2K mdx cells and in vivo in the mdx mouse model.", 
    "editor": [
      {
        "familyName": "Bernardini", 
        "givenName": "Camilla", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4939-7374-3_12", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4939-7373-6", 
        "978-1-4939-7374-3"
      ], 
      "name": "Duchenne Muscular Dystrophy", 
      "type": "Book"
    }, 
    "name": "The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy", 
    "pagination": "171-183", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4939-7374-3_12"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e18a06d8945c4aeafedd945e5e24f687cedcbab50f8e9cda86b01b794c349738"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092345489"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29067663"
        ]
      }
    ], 
    "publisher": {
      "location": "New York, NY", 
      "name": "Springer New York", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4939-7374-3_12", 
      "https://app.dimensions.ai/details/publication/pub.1092345489"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2019-04-16T00:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8697_00000493.jsonl", 
    "type": "Chapter", 
    "url": "http://link.springer.com/10.1007/978-1-4939-7374-3_12"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-7374-3_12'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-7374-3_12'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-7374-3_12'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-7374-3_12'


 

This table displays all metadata directly associated to this object as RDF triples.

145 TRIPLES      23 PREDICATES      46 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4939-7374-3_12 schema:about N264cb94981134a44afc69d798ce9bdf5
2 N2ce1cf90a5bc434fb48fe384e171f492
3 N31c559a9d83440e680b2a24c9fab5ab7
4 N3cc922ec50b84575b0876de6de7e293a
5 N582861c2ba9f496696c8539ae6fe6f50
6 N692ba94fb4874cc1a654b87858ded69b
7 N91e4d02cd08243218adc8cba8683654b
8 Na02f1ad59b184a6387629b1b337576f2
9 Na6bd21e92e104e68ae1ef4d87e072bdd
10 Na86475445155423f994a21ade871b451
11 Nc5a7be9a9fa24dd0bbe8dd2709f0812d
12 anzsrc-for:10
13 anzsrc-for:1004
14 schema:author Nb83a0ccfc16b42d8a13ca21d2221eb8b
15 schema:citation sg:pub.10.1038/nm.3765
16 https://doi.org/10.1006/dbio.1994.1103
17 https://doi.org/10.1016/j.coph.2015.07.005
18 https://doi.org/10.1073/pnas.81.4.1189
19 https://doi.org/10.1093/nar/29.9.e45
20 https://doi.org/10.1093/nar/gkp841
21 https://doi.org/10.3233/jnd-160146
22 schema:datePublished 2018
23 schema:datePublishedReg 2018-01-01
24 schema:description Antisense oligonucleotides (AONs) hold great promise for therapeutic splice-switching correction in many genetic diseases and in particular for Duchenne muscular dystrophy (DMD), where AONs can be used to reframe the dystrophin transcript and give rise to a partially deleted but yet functional dystrophin protein. Many different chemistries of AONs can be used for splice switching modulation, and some of them have been evaluated in clinical trials for DMD. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake, and sufficient therapeutic efficacy is difficult to achieve. Therefore, there is still a critical need to develop efficient AONs able to restore the expression of dystrophin in all relevant tissues and international efforts are currently on going to develop new compounds or alternative chemistries with higher therapeutic potential. Here, we describe the methods to evaluate the potency of antisense oligonucleotides, and in particular of tricyclo-DNA (tcDNA)-AONs, a novel class of AONs which displays unique pharmacological properties and unprecedented uptake in many tissues after systemic administration. We focus on the most widely used mouse model for DMD, the mdx mouse and detail methods to analyze the skipping of the mouse exon 23 both in vitro in H2K mdx cells and in vivo in the mdx mouse model.
25 schema:editor Ne2d196324e01407b9cab637eedd4461b
26 schema:genre chapter
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N125e6eb8faab4b7c8c1699dc2edcc708
30 schema:name The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy
31 schema:pagination 171-183
32 schema:productId N01b619edba0049ecb11c7740c9ef9d9f
33 N19177efb8b6a4c6a803395d7bd2e21df
34 N40faaedd3a59417ba3d8197372d3b383
35 Nf603fe4657d34a17a8c5cd748a23e0b4
36 schema:publisher N454c6a60f9844b799a5b300e02d8eaee
37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092345489
38 https://doi.org/10.1007/978-1-4939-7374-3_12
39 schema:sdDatePublished 2019-04-16T00:18
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher N3f5f37fbc57d48a18b68cf999fbea4fd
42 schema:url http://link.springer.com/10.1007/978-1-4939-7374-3_12
43 sgo:license sg:explorer/license/
44 sgo:sdDataset chapters
45 rdf:type schema:Chapter
46 N01b619edba0049ecb11c7740c9ef9d9f schema:name readcube_id
47 schema:value e18a06d8945c4aeafedd945e5e24f687cedcbab50f8e9cda86b01b794c349738
48 rdf:type schema:PropertyValue
49 N125e6eb8faab4b7c8c1699dc2edcc708 schema:isbn 978-1-4939-7373-6
50 978-1-4939-7374-3
51 schema:name Duchenne Muscular Dystrophy
52 rdf:type schema:Book
53 N19177efb8b6a4c6a803395d7bd2e21df schema:name pubmed_id
54 schema:value 29067663
55 rdf:type schema:PropertyValue
56 N264cb94981134a44afc69d798ce9bdf5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Humans
58 rdf:type schema:DefinedTerm
59 N2ce1cf90a5bc434fb48fe384e171f492 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Mice, Inbred mdx
61 rdf:type schema:DefinedTerm
62 N31c559a9d83440e680b2a24c9fab5ab7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Muscular Dystrophy, Duchenne
64 rdf:type schema:DefinedTerm
65 N3cc922ec50b84575b0876de6de7e293a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Genetic Therapy
67 rdf:type schema:DefinedTerm
68 N3f5f37fbc57d48a18b68cf999fbea4fd schema:name Springer Nature - SN SciGraph project
69 rdf:type schema:Organization
70 N40faaedd3a59417ba3d8197372d3b383 schema:name dimensions_id
71 schema:value pub.1092345489
72 rdf:type schema:PropertyValue
73 N454c6a60f9844b799a5b300e02d8eaee schema:location New York, NY
74 schema:name Springer New York
75 rdf:type schema:Organisation
76 N54613a703fb0449c94a78de11e67aa4c schema:familyName Bernardini
77 schema:givenName Camilla
78 rdf:type schema:Person
79 N582861c2ba9f496696c8539ae6fe6f50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Dystrophin
81 rdf:type schema:DefinedTerm
82 N692ba94fb4874cc1a654b87858ded69b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Muscle, Skeletal
84 rdf:type schema:DefinedTerm
85 N91e4d02cd08243218adc8cba8683654b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Exons
87 rdf:type schema:DefinedTerm
88 Na02f1ad59b184a6387629b1b337576f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Disease Models, Animal
90 rdf:type schema:DefinedTerm
91 Na6bd21e92e104e68ae1ef4d87e072bdd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Oligonucleotides, Antisense
93 rdf:type schema:DefinedTerm
94 Na86475445155423f994a21ade871b451 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Mice
96 rdf:type schema:DefinedTerm
97 Nb83a0ccfc16b42d8a13ca21d2221eb8b rdf:first sg:person.01026571624.29
98 rdf:rest Nf4cd003a19784bc38fa76794361e8624
99 Nc5a7be9a9fa24dd0bbe8dd2709f0812d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Animals
101 rdf:type schema:DefinedTerm
102 Ne2d196324e01407b9cab637eedd4461b rdf:first N54613a703fb0449c94a78de11e67aa4c
103 rdf:rest rdf:nil
104 Nf03324d8112f47548bce912b7df6cdcb schema:name Université de Versailles St-Quentin en Yvelines
105 rdf:type schema:Organization
106 Nf4cd003a19784bc38fa76794361e8624 rdf:first sg:person.01200571036.55
107 rdf:rest rdf:nil
108 Nf603fe4657d34a17a8c5cd748a23e0b4 schema:name doi
109 schema:value 10.1007/978-1-4939-7374-3_12
110 rdf:type schema:PropertyValue
111 anzsrc-for:10 schema:inDefinedTermSet anzsrc-for:
112 schema:name Technology
113 rdf:type schema:DefinedTerm
114 anzsrc-for:1004 schema:inDefinedTermSet anzsrc-for:
115 schema:name Medical Biotechnology
116 rdf:type schema:DefinedTerm
117 sg:person.01026571624.29 schema:affiliation https://www.grid.ac/institutes/grid.12832.3a
118 schema:familyName Relizani
119 schema:givenName Karima
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026571624.29
121 rdf:type schema:Person
122 sg:person.01200571036.55 schema:affiliation Nf03324d8112f47548bce912b7df6cdcb
123 schema:familyName Goyenvalle
124 schema:givenName Aurelie
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200571036.55
126 rdf:type schema:Person
127 sg:pub.10.1038/nm.3765 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014266352
128 https://doi.org/10.1038/nm.3765
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1006/dbio.1994.1103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015861224
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1016/j.coph.2015.07.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002005310
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1073/pnas.81.4.1189 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001793181
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1093/nar/29.9.e45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030834024
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1093/nar/gkp841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005271115
139 rdf:type schema:CreativeWork
140 https://doi.org/10.3233/jnd-160146 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013977294
141 rdf:type schema:CreativeWork
142 https://www.grid.ac/institutes/grid.12832.3a schema:alternateName Versailles Saint-Quentin-en-Yvelines University
143 schema:name Université de Versailles Saint-Quentin en Yvelines
144 Université de Versailles St-Quentin en Yvelines
145 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...